Flamel Shares Up on Wyeth Deal Announcement

French biopharmaceutical company Flamel Technologies said Wednesday it signed a development and license agreement with the pharmaceuticals unit of drug developer Wyeth.

The deal is to develop and license a marketed protein to be delivered using Flamel's Medusa technology. Flamel will receive an upfront payment and potential development fees, milestones and royalty payments from Wyeth , the terms of which were not disclosed.

Flamel's shares rose as much as 66 cents, or 7.2 percent, to $9.80 in Wednesday morning trading on the Nasdaq. The stock has traded in the 52-week range of $8.59 and $37.42.

Contact Health Care


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.